Autologous and Donor-derived CD7 CAR T-cell Therapy in Refractory or Relapsed T-cell Malignancies: a Multi-center, Open-label, Phase Ⅰ/Ⅱ Clinical Trial
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 4
- 主要终点
- Dose-Limiting Toxicity (DLT) in phase I
研究概览
简要总结
This is a multi-center, open-label, non-randomized, phase I/II trial. Patients with refractory or relapsed T-cell malignancies will receive autologous, prior-HSCT donor-derived or new donor-derived CD7 CAR T cells according to their HSCT history, peripheral blood leukemia burden and at their discretion. The primary objective is to learn about the safety of autologous, prior-HSCT donor-derived and new donor-derived CD7 CAR T-cell therapy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia and lymphoma (r/r T-ALL/T-LBL) in phase I and to learn about the efficacy of autologous, prior-HSCT donor-derived and new donor-derived CD7 CAR T-cell therapy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia and lymphoma (r/r T-ALL/T-LBL) in phase II. The primary endpoint is type and incidence of dose limiting toxicity (DLT) within 21 days after CD7 CAR T-cell infusion in phase I and overall response rate (ORR), which includes CR, CRh, CRi, MLFS, aplastic marrow for blood and bone marrow; central nervous system (CNS) remission; CR and PR for lymphomatous extramedullary disease according to National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia at 3 months (± 1 week) post CD7 CAR T-cell infusion in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells in phase II. A total number of 80 subjects will be enrolled.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Only patients who meet all the following criteria can be included in the group:
- •CD7-positive refractory or relapsed T-cell malignancies with progression or intolerance after all standard treatments, limited prognosis from currently available treatments and no available treatment options (e.g. HSCT or chemotherapy).
- •Tumor cells in bone marrow or cerebrospinal fluid are positive for CD7 antigen by flow cytometry or tumour tissue is positive for CD7 by immunohistochemistry (CD7 antigen positivity by flow cytometry: >80% of tumour cells expressing CD7 with a mean fluorescence intensity [MFI] of CD7 similar to that of normal T cells are considered to have fully positive expression; >80% of tumor cells expressing CD7 but with an MFI of CD7 at least 1 log lower than that of normal T cells are considered to have low expression [dim]; tumor cells with a CD7 expression rate between 20-80% are considered to have partial expression; CD7 antigen positivity by pathological immunohistochemistry: >30%);
- •Male or female, age 1-70 years;
- •No severe allergic constitution;
- •Eastern Cooperative Oncology Group (ECOG) performance status score (Oken et al., 1982) of 0-2;
- •Life expectancy of at least 60 days as determined by the investigator;
- •Provide a signed informed consent form prior to any screening procedures; subjects volunteering to participate in the study should be capable of understanding and signing the informed consent form and be willing to follow the study visit schedule and associated study procedures as specified in the protocol. Subjects aged 19-70 years old need to be sufficiently aware and capable of signing the informed consent form; subjects aged 1-7 years can be recruited after legal guardians or patient advocates sign the informed consent form; subjects aged 8-18 years need to be sufficiently aware and able to sign the informed consent form, and their legal guardians or patient advocates also need to sign the informed consent form.
排除标准
- •Patients with at least one of the following conditions are excluded:
- •Intracranial hypertension or unconscious;
- •Acute heart failure or severe arrhythmia;
- •Acute respiratory failure;
- •Other types of malignant tumors;
- •Diffuse intravascular coagulation;
- •Serum creatinine and/or blood urea nitrogen over 1.5 times the normal value;
- •Sepsis or other uncontrolled infection;
- •Uncontrolled diabetes mellitus;
- •Severe psychological disorder;
- •Obvious cranial lesions by cranial MRI;
- •Allergic constitution;
- •Organ recipients;
- •Pregnant or breastfeeding;
- •Active, uncontrolled infection, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or treponema pallidum (TP).
研究组 & 干预措施
Arm-1
Autologous CD7 CAR T-cell treatment
干预措施: Autologous CD7 CAR T-cell (Drug)
Arm-2
Prior-HSCT donor-derived CD7 CAR T-cell treatment
干预措施: Prior-HSCT donor-derived CD7 CAR T-cell (Drug)
Arm-3
New donor-derived CD7 CAR T-cell treatment
干预措施: New donor-derived CD7 CAR T-cell (Drug)
结局指标
主要结局
Dose-Limiting Toxicity (DLT) in phase I
时间窗: 21 days post infusion
Type and incidence of dose-limiting toxicity (DLT) within 21 days after CD7 CAR T-cell infusion
Overall Response Rate (ORR) in phase II
时间窗: 3 months (± 1 week) post infusion
Overall response rate (ORR), which includes CR, CRh, CRi, MLFS, aplastic marrow for blood and bone marrow; central nervous system (CNS) remission; CR and PR for lymphomatous extramedullary disease per National Comprehensive Cancer Network (NCCN) Guidelines Version 3.2023 of Acute Lymphoblastic Leukemia at 3 months (± 1 week) post CD7 CAR T-cell infusion in refractory or relapsed T-cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/T-LBL) patients treated with CD7 CAR T cells
次要结局
- Overall Response Rate (ORR) in phase I(3 months (± 1 week) post infusion)
- Levels of CAR transgene in phase II(2 years post infusion)
- Levels of immune cells in phase II(2 years post infusion)
- Levels of cytokines in phase II(2 years post infusion)
- Safety in phase II(2 years post infusion)
- Progression-Free Survival (PFS) in phase II(2 years post infusion)
- Duration of Remission (DOR) in phase II(2 years post infusion)
- Overall Survival (OS) in phase II(2 years post infusion)
- Levels of CD7 CAR-T Cells in phase II(2 years post infusion)
研究者
Jing Pan
Director of Dept of Hemato-Oncology and Immunotherapy
Beijing GoBroad Hospital